Retroviral protease inhibitors (RPIs) such as lopinavir (LP) and saquinavir (SQ) are active against Plasmodium parasites. However, the exact molecular target(s) for these RPIs in the Plasmodium parasites remains poorly understood. We hypothesised that LP and SQ suppress parasite growth through inhibition of aspartyl proteases. Using reverse genetics approach, we embarked on separately generating knockout (KO) parasite lines lacking Plasmepsin 4 (PM4), PM7, PM8, or DNA damage-inducible protein 1 (Ddi1) in the rodent malaria parasite Plasmodium berghei ANKA. We then tested the suppressive profiles of the LP/Ritonavir (LP/RT) and SQ/RT as well as antimalarials; Amodiaquine (AQ) and Piperaquine (PQ) against the KO parasites in the standard 4-day suppressive test. The Ddi1 gene proved refractory to deletion suggesting that the gene is essential for the growth of the asexual blood stage parasites. Our results revealed that deletion of PM4 significantly reduces normal parasite growth rate phenotype (P = 0.003). Unlike PM4_KO parasites which were less susceptible to LP and SQ (P = 0.036, P = 0.030), the suppressive profiles for PM7_KO and PM8_KO parasites were comparable to those for the WT parasites. This finding suggests a potential role of PM4 in the LP and SQ action. On further analysis, modelling and molecular docking studies revealed that both LP and SQ displayed high binding affinities (-6.3 kcal/mol to -10.3 kcal/mol) towards the Plasmodium aspartyl proteases.
Introduction
Notwithstanding the immense investments in malaria control programs to date, it remains to be a significant global health problem in most regions of the world including Africa, Asia and parts of the Eastern Mediterranean Region (1,2) . The sub-Saharan part of Africa continues to bear the highest burden of the disease with over 90% of the cases occurring in this region, especially in children under five years of age. In the year 2016 alone, an estimated 285 000 children succumbed to malaria in Africa (2).
The emergence and spread of resistance to available drugs including the artemisinin-based combination therapies (ACTs) have aggravated the burden of the malaria disease. Incidences of parasite resistance to the ACTs were first reported in western Cambodia and currently slowly spreading to other parts of Asia. The South East Asia region occupies a historical record as a site of emerging resistance to the previous first-line antimalarial therapies which later rapidly spread across the African countries where malaria transmission is consistently high (3) (4) (5) (6) . Since the options of drugs for which the human malaria parasite Plasmodium falciparum has not evolved resistance is rapidly diminishing, new and rational approaches to the prevention and treatment of malaria infections are urgently needed.
The burden of malaria is compounded with HIV/AIDS infections which are also concentrated in the malaria-endemic regions, primarily sub-Saharan Africa. This geographical overlap has raised opportunities and concerns for potential immunological, social, therapeutic and clinical interactions (7) . Previous studies have demonstrated that the antiretroviral therapy, especially RPIs exert a potent effect against both the drug-sensitive and drug-resistant P.
falciparum (8) (9) (10) (11) (12) (13) (14) , as well as a reduction in the incidence of malaria (15). For instance, seven RPIs inhibit the development of P. falciparum parasites in vitro with lopinavir yielding moderate synergy with lumefantrine (12). The RPIs are typical examples of drugs that target an aspartyl protease in HIV, HIV-1 aspartyl protease (16, 17) . Like in HIV, aspartyl proteases play essential roles in the biology of Plasmodium parasites and thus are "druggable" targets (18) (19) (20) (21) . The blood stage aspartyl proteases are responsible for host haemoglobin digestion, rupturing of the host erythrocytes (22), as well as processing of effector proteins for export to the infected erythrocytes (23). The RPIs are predicted to exert their antimalarial activity in the blood stages of parasite life cycle (8, 13) . Previous studies geared towards understanding the mode of action of the RPIs in suppressing the growth of Plasmodium parasites focused on pepsin-like proteases (PMs) even though Plasmodium species express a retropepsin-like protease, referred to as Ddi1 (24).
Using the rodent malaria parasite, P. berghei, and highly efficient PlasmoGEM genetic modification vectors, we engineered the Plasmodium aspartyl proteases; PM4, PM7, PM8 and Ddi1 in our quest to understand the possible mechanisms of action of LP and SQ (the most active RPIs). Here, we report that the PM4 and Ddi1 genes are essential for asexual blood stage parasite, but PM7 and PM8 genes are not. We further discuss the growth rate phenotypes of the KO parasites lacking PM7, PM8 or PM4 genes as well as the in vivo susceptibility profiles of the KO parasites to LP and SQ. Finally, using modeling and molecular docking, we predict the in silico binding affinities of the LP and SQ towards PM4, PM7, PM8 or Ddi1. The findings reveal that PM4 assures parasite fitness in the asexual stage, mediates the possible mechanism of action of LP and SQ in parasite growth suppression as well as the refractory nature of Ddi1. Here, we for the first time provide evidence that the retropepsin-like protease is essential for the asexual stage of the malaria parasite.
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Materials and Methods
Parasites, vectors, hosts and test compounds
A transgenic P. berghei ANKA strain 676m1cl1{PbGFP-LUC(con)} which expresses a fusion protein GFP-Luciferase (25), maintained in cryopreserved stocks in Kenya Medical Research Institute (KEMRI), was used in this study. The KO vectors (PbGEM-039254, PbGEM-086320, PbGEM-057101, and PbGEM-097527) were obtained under a material transfer agreement with the PlasmoGEM project at the Wellcome Trust Sanger Institute (PG-MTA-0093). Naive male Swiss albino mice (6-7 weeks old), weighing 18-20g were acquired from the KEMRI animal house and used as models in this study. The animals were kept in the KEMRI animal house in standard polypropylene cages and fed on commercial rodent feed and water ad libitum. LP, SQ and RT were purchased from Sigma Aldrich (USA). All the test compounds were prepared by solubilising them in a solution consisting of 70% Tween-80 (density=1.08gml -1 ) and 30% ethanol (density=0.81 gml -1 ) and were diluted ten times with distilled water. The diluted Tween-80 and ethanol solution was used as a vehicle and control for the drug profile assays.
Ethics Statement
All protocols were conducted in accordance with prior approvals obtained from the Kenya 
Generation of the knockout parasite lines
Isolation, digestion, and purification of vector DNA. Plasmid DNAs were isolated from overnight cultures of E. coli (vector hosts) in terrific broth (TB) supplemented with kanamycin using QIAfilter Plasmid Midi Kit. The isolated plasmid was prepared for transfection by Not1 restriction digestion to liberate the vector backbone and was purified using standard ethanol precipitation. Each isolated construct was dried at 65°C for 5 min, dissolved in 10 µl of PCR water and the plasmid DNA concentration determined in a 1μl sample volume using a NanoDrop. Both restriction digestion and diagnostic polymerase chain reaction (PCR), using QCR2/GW2 primer pair, were used as vector verification strategies.
Collection of the P. berghei schizonts for transfection. Collection of the P. berghei schizonts for transfection was done using standard protocols as described by (26). Briefly, for each of the vectors, at least three mice were used for schizont culture. P. berghei parasites were propagated by intraperitoneal (IP) injection into the mice and were harvested for schizont culture at 3% parasitaemia using cardiac puncture. The asexual stage parasites (rings) were cultured in vitro at 37°C in tightly sealed and gassed flasks containing 100ml of schizont culture medium (72 ml RPMI1640, 25 ml freshly thawed FBS, 1ml of antibiotic Pen/Strep (1:100 Penicillin/streptomycin) and 2ml 0.5M NaHC03). Each flask contained 2ml of blood and was incubated overnight, in a shaker incubator. The schizonts were harvested after 22 hours, purified by Nycodenz density gradient centrifugation and each pellet re-suspended in schizont culture media, ready for transfection.
Transfection, selection and genotype analysis of mutant parasites. For every transfection, 20μl of schizont pellet was used. Parasite pellet was re-suspended in 100μl AMAXA supplemented nucleofector solution containing purified vector DNA. Exactly 100μl of the solution (vector DNA /nucleofector solution and schizonts) were pipetted into the Amaxa cuvette. The electroporation was done using program U33 of the Nucleofector 2B Device (Lonza). The electroporated parasites were injected intravenously (IV) into mice (two mice per transfection). Twenty-four hours post parasite inoculation, pyrimethamine drug (7 mg/mL), in drinking water, was provided to the mice for nine days. To generate a genetically homogenous parasite, the KO parasites were diluted to approximately 0.1%, passaged successively three times in naïve mice each time under the Pyrimethamine selection pressure. After cloning the recovered KO parasites, the genomic DNA (gDNA) was extracted and purified using QIAamp DNA Mini Kit following instructions from the manufacturer. The diagnostic and genotyping PCR analysis was used to genotype the KO lines using three primer pairs; QCR2/GW2, GT/GW1 or GW2 and QCR1/QCR2. QCR1 and QCR2 anneal to the genomic sequence of the targeted locus, GT anneals to the genomic sequence outside of but preceding the region covered by the gDNA clone, while GW1/2 anneals to the sequence of the selectable marker cassette (human dihydrofolate reductase; hDHFR), (Table 1A , 1B and 1C).
The PCR amplification was done using 2xGoTag Green master mix for thirty cycles with an annealing temperature of 50°C and an extension temperature of 62°C. The PCR amplicons were analysed on a 1% agarose gel electrophoresis. 
Data Presentation and Statistical Analysis
The parasitaemia data from microscopy were analysed using R software. Boxplots were generated to portray the KO growth trends and parasite densities in presence and absence of the test drugs. Using the Student's t-test in the Stata version 15.1 software, we computed means of percentage drug activity/percentage parasitaemia from each mouse in the treated group and compared them to that from mice in the control group.
Molecular docking
Homology modelling and structure validation. 
Results
Generation of the PM4, PM7, PM8 or Ddi1 knockout parasites: The Ddi1 gene was refractory to deletion thus essential for the growth of the asexual blood stage parasites
Overall, the transfection experiments yielded a total of three KO parasite lines. Of the three mice infected with schizonts transfected with PbGEM-039254 targeting the PM4, two mice had developed parasitaemia of >4% by day eight post parasite inoculation (7 days of pyrimethamine treatment). All the three mice infected with schizonts transfected with PbGEM-086320 and PbGEM-057101 targeting the PM7 and PM8 were parasite positive by day six post parasite inoculation. Three successive attempts to delete the Ddi1 failed to recover parasite twenty days post infection suggesting that the Ddi1 gene was refractory to deletion and thus essential for the asexual blood stage parasite growth. We then proceeded to genotype the PM4, PM7 and PM8 KO parasite lines using three sets of primers; QCR2/GW2, GT/GW1(2) and QCR1/QCR2. Both the WT and KO parasite genomic DNA (gDNA) was isolated and diagnostic polymerase chain reaction (PCR) amplification conducted. As expected, using the standard GW2 and the vector specific QCR2 primers, we obtained a fragment of 1kb, 0.8kb, and 1kb in PM4, PM7 and PM8 parasite lines (Fig 1) indicating the presence of the vector within the parasite. The PCR amplification using vector specific quality control primers, the QCR1 and QCR2 only amplified in the WT parasite line but failed to amplify in the KO lines confirming successful deletion of the respective genes. To further confirm correct integration of the specific vector into the correct chromosome and position, we utilized the standard primers GW1 or GW2 and the vector-specific primers GT. As expected, we obtained a PCR product of 2.9kb, 2.1kb and 2.6kb for PM4, PM7
and PM8 respectively. These results affirmed the successful generation of the KO parasite lines 13 here referred to as PM4_KO, PM7_KO and PM8_KO. We used these parasite lines to assay drug response profiles with WT parasites as the reference line. 
The PM7_KO and PM8 KO lines remained sensitive to LP and SQ while the PM4_KO line lost significant susceptibility to both LP and SQ
We assayed whether the deletion of the PM4, PM7 or PM8 affected susceptibility to LP, SQ, PQ and AQ. We reasoned that if the PM4, PM7 or PM8 are targets for the LP and SQ drugs, the KO parasite lines would lose susceptibility to the drugs. We determined the parasite susceptibility by calculating the activity of LP/RT at 40mg/kg.10mg/kg, SQ/RT at 50mg/kg.5mg/kg, AQ at (2.5 mg/kg and 1.25mg/kg) and PQ at (2.5mg/kg and 1.25mg/kg) on day four post parasite infection. The LP/RT significantly reduced the PM4_KO mutants' parasitemia by 5.01% compared to a 15.71% in the WT parasites (P = 0.036). Similarly, the SQ/RT reduced PM4_KO mutants' parasitemia by 5.29% compared to a 14.12% against the WT parasites (P = 0.030) ( Fig 3B) . However, the activity of both the LP/RT and SQ/RT against the PM7_KO and PM8_KO parasites were comparable to the percentage activity of WT parasites (Fig 3C and 3D) .
As expected, AQ and PQ were active against the WT parasites. At the 2.5mg/kg and 1.25mg/kg of AQ or PQ, the mutant parasite remained equally susceptible. 
Both the LP and SQ exhibited higher binding affinity for PM4 protein than PM7, PM8 or Ddi1
To estimate the degree of correctness for all the modeled structures, the Z-scores from PROSA-web server were determined and the proteins scored -5.09, -9.11, -7.94 and -7.52 for Ddi1, PM4, PM7 and PM8 respectively. The Z-scores implied that the structures of the modeled proteins were within the range of scores typically found with experimentally defined proteins. The averaged 3D-ID values were obtained from VERIFY 3D while PROCHECK confirmed residue positioning in the 3D structures and the values confirmed the integrity of the modeled structures (Table 2) . The 3D structures of the proteins were modelled using SWISS-MODEL, and their quality validated using PROCHECK for stereochemical evaluation; PRoSA-web, for detection of potential errors in the 3D structures; and verify_3D, for compatibility of the 3D structures with their respective amino acid sequences.
All the modelled structures have features characteristic of native structures.
When we evaluated the protein binding affinity, we determined the ligand conformations using the AutoDock Tools (ADT; Fig 4) , and the best binding modes (mode 1). All the protein binding complexes showed high binding affinities, with the highest affinity at -10.6 kcal/mol and the lowest at -6.3 kcal/mol. Unlike the Ddi1 that had an equal binding affinity as HIV-1 asp protease for LP (-6.3 kcal/mol), the binding affinities of LP or SQ to PM4, PM7 or PM8 were 19 higher than the affinity of the two drugs to the HIV-1 aspartyl protease (-6.3 kcal/mol). The PM4
had the lowest binding energy; -9.3 and -10.6 kcal/mol for LP or SQ respectively, indicating better binding with the LP and SQ (Figs 4 and 5 ). 
The Ddi1 has a pepsin_retropepsin-like domain conserved across all Plasmodium species
We then reasoned that since deletion of the Ddi1 seemed toxic to the growth of the asexual blood stage parasites, the protein might have unique and conserved motifs across the different malaria parasites. We searched and analysed conserved motifs in the Ddi1 gene sequence using the Batch CD-Search (36) in the Conserved Domain Database (CDD). The CD-search results revealed that Ddi1 gene has a pepsin_retropepsin-like domain, with a catalytic motif, within its sequence. Interestingly, this motif is conserved in all the eight Plasmodium species that compared in our analysis ( Fig 6) . of the Ddi1 to the LP coupled with its essential role in the growth of the asexual blood parasite 20 suggest that chemical compounds that inhibit the Ddi1 may form next generation of novel drugs. 21
To study the role of other aspartyl proteases in mediating drug action, we used the 22 generated KO lines (PM4_KO, PM7_KO, and PM8_KO) to investigate the effect of gene deletion 23 23 on the parasite growth rate phenotypes. Although a recent study on the functional profile of 24
Plasmodium genome deleted the genes in P. berghei, the effect of the gene deletion on drug 25 susceptibility was not measured (40). In agreement with this study, we have demonstrated that, 26 whereas the PM7 and PM8 genes are dispensable during the asexual stages of parasite 27 development, they exhibit an indirect interaction with asexual stage expressions. The loss of PM7 28 and PM8 genes increased the growth rate of asexual blood stage parasites suggesting that the 29 deletion confer a growth advantage to the KO parasite. At D4 PI, the parasitemia for the PM7_KO 30 and PM8_KO parasites was 2.5-fold higher than that of the WT parasites. On further scrutiny, we 31 observed that, despite the PM4 being a dispensable gene, its deletion significantly reduces parasite 32 asexual stage growth rates, Fig 2. The parasitemia for PM4_KO parasites was 2-fold lower than 33 that of the WT parasites, suggesting a substantial contribution to the fitness of the parasite within 34 the red blood cells. Whereas P. falciparum expresses four digestive vacuoles (DV) PMs; (PM 1, 35 2, histo-aspartic protease; HAP and PM4), there is only one identified DV PM in P. berghei, PM4. 36 Therefore, successful deletion of PM4 in P. berghei suggests that the parasite could be relying on 37 other enzyme pathways for haemoglobin degradation that sustains the supply of the amino acids 38 for the intraerythrocytic parasite growth. The findings of PM4 deletion in P. berghei are consistent 39 with the findings from (18), who documented that a quadruple KO of all the DV PMs (PM1, PM2, 40 HAP, and PM4) in P. falciparum does not entirely impair parasite growth. However, the effect of 41 the quadruple gene KO on drug susceptibility was not determined. 42
Malaria parasite haemoglobin degradation is a vital process during intra-erythrocytic 43 parasite development. The plasmepsins, aminopeptidases, metalloprotease, falcilysin, and 44 falcipains are found in the DV and are involved in degrading the haemoglobin. The presence of 45 multiple enzyme pathways with overlapping specificity and function is strategic to increase 46 24 parasite fitness (41, 42) . As earlier alluded, the deletion of PM4 confers significant growth 47 disadvantage, and the KO parasite is less susceptible to LP and SQ. We thus argue that since the 48 PM4 participates in the haemoglobin degradation (22,43), then the protein may be a target for both 49 the LP and SQ. However, the presence of alternative enzymes for haemoglobin degradation 50 provides the asexual blood stage parasites with an advantage albeit with cost in the growth rate. 51
Our drug profile results show that the activity of all the tested drugs against PM7_KO and 52 PM8_KO parasites was nearly equivalent to the WT parasites. The activity of LP/RT and SQ/RT 53 ranged between 15% and 21% against both the mutant parasites and WT parasites. These findings 54 augment the fact that the asexual parasites do not express the PM7 and PM8 genes within the 55 erythrocytes (42,43). Our study focused on the asexual blood stage parasites; both the LP and SQ 56 are predicted to act on the parasite within the erythrocytes, thus although the LP and SQ may bind 57 PM7 and PM8, the inhibition effect may not be observed in the asexual parasites within the 58 erythrocytes. Indeed, studies involving PM8 have shown that it plays an essential role in the 59 sporogonic stages of malaria parasite development (44). On the contrary, compared to the WT 60 parasites, the LP/RT or SQ/RT activity against PM4_KO lines was 3-fold lower, demonstrating a 61 potential role in the LP and SQ action, Fig 3. The PM4 is the only DV specific PM found in all 62
Plasmodium species suggesting an essential role for the protein in the growth of the asexual blood 63 stage parasite (45). 64
The modeling and molecular docking studies revealed that LP or SQ have high binding 65 energies towards the Plasmodium aspartyl proteases. In fact, the drugs' binding affinity towards 66 PM4, PM7, PM8 or Ddi1 were higher than the affinity towards the HIV-1 aspartyl protease. 67
However, because parasites contain many proteases with functional redundancy, unlike 68 retroviruses, the in vivo activity of LP and SQ against the parasites is not proportional to the in 69 25 silico binding affinities. The high binding affinity of LP or SQ towards PM4 correlates with the 70 reduced sensitivity of PM4_KO parasites to the drugs. However, because of the redundant enzyme 71 system involved in haemoglobin digestion for parasite asexual stage development, inhibition of 72 PM4 does not entirely deprive of parasite survival. The high binding affinity shown by LP or SQ 73 towards PM7 or PM8 (-8.4 kcal/mol to -9.4 kcal/mol) does not correlate with the in vivo drug 74 suppression of asexual stage parasites probably because the enzymes are not essential and thus 75 possibly not expressed during the erythrocytic asexual stages of parasite growth. Future work 76 tailored towards understanding the functions of Ddi1 in Plasmodium parasites and its candidature 77 as a target for drugs may inform the development of future drugs against the malaria parasite. 78
